Jan 22 (Reuters) - Nabi Biopharmaceuticals (NABI.O) said it named Raafat Fahim as president and chief executive officer, succeeding Leslie Hudson, who had served as interim CEO since February 2007. Fahim most recently was the chief operating officer and general manager of the company's Biologics Strategic Business Unit, the drugmaker said in a statement. (Reporting by Sreerupa Mitra in Bangalore; Editing by Pratish Narayanan)
Experts say there is no single answer to solving global warming, but a handful of technologies could be promising. Check out some of the candidates and join the debate. Full Article
The House of Representatives approved the biggest changes in financial regulation since the Great Depression, marking a win for the Obama administration and congressional Democrats. Full Article
Fear of the market abyss has faded for investors, but another fear is lurking on the horizon, if not already here. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
